Insider trade

Arrowhead Pharmaceuticals (ARWR)Director sold ~$206K

Adeoye Y Olukotun, Director at Arrowhead Pharmaceuticals, sold ~$206K of Arrowhead Pharmaceuticals shares.

~$206K
Approx. value · 3,090 sh @ $66.70: 41K
Holds after · shares reported

Traded: Dec 19, 2025
Filed: Dec 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Nov 25, 2025Company filing · Form 8-K · ResultsReported its results
Nov 28, 2025InsiderDirector sold ~$493K of ARWR shares in the open market
Dec 5, 2025InsiderDirector sold ~$992K of ARWR shares in the open market
Dec 15, 2025Insider · 1 personInsiders: 3 sales (~$9.0M)
Dec 16, 2025Insider · 1 personInsiders: 9 sales (~$3.4M)
Dec 17, 2025Insider · 1 personInsiders: 4 sales (~$5.4M)
Dec 19, 2025 · this disclosureInsiderDirector sold ~$206K of ARWR shares in the open market

What came next

Dec 19, 2025Insider · 4 peopleInsiders: 11 sales (~$2.6M)
Dec 22, 2025Insider · 1 personInsiders: 2 sales (~$861K)
Dec 26, 2025InsiderDirector sold ~$527K of ARWR shares in the open market
Dec 29, 2025Insider · 1 personInsiders: 2 sales (~$3.6M)
Jan 2, 2026Insider · 1 personInsiders: 2 sales (~$872K)
Jan 5, 2026Insider · 2 peopleInsiders: 19 sales (~$5.7M)
Jan 7, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
Jan 12, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
Feb 5, 2026Company filing · Form 8-K · ResultsReported its results
Mar 5, 2026InsiderOfficer sold ~$642K of ARWR shares in the open market

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Arrowhead Pharmaceuticals

For Arrowhead Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARWR page.

Other recent filings by Adeoye Y Olukotun, Director

The full history of Adeoye Y Olukotun, Director is on the profile page.

How this filing works

Other disclosures at Arrowhead Pharmaceuticals

Everything OQRO holds on this company is on its ARWR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data